Literature DB >> 15897827

Human intervertebral disc aggrecan inhibits endothelial cell adhesion and cell migration in vitro.

William E B Johnson1, Bruce Caterson, Stephen M Eisenstein, Sally Roberts.   

Abstract

STUDY
DESIGN: The effect of human intervertebral disc aggrecan on endothelial cell growth was examined using cell culture assays.
OBJECTIVE: To determine the response of endothelial cells to human intervertebral disc aggrecan, and whether the amount and type of aggrecan present in the intervertebral disc may be implicated in disc vascularization. SUMMARY OF BACKGROUND DATA: Intervertebral disc degeneration has been associated with a loss of proteoglycan, and the ingrowth of blood vessels and nerves. Neovascularization is a common feature also of disc herniation. Intervertebral disc aggrecan is inhibitory to sensory nerve growth, but the effects of disc aggrecan on endothelial cell growth are not known.
METHODS: Aggrecan monomers were isolated separately from the anulus fibrosus and nucleus pulposus of human lumbar intervertebral discs, and characterized to determine the amount and type of sulfated glycosaminoglycan side chains present. The effects of these aggrecan isolates on the cellular adhesion and migration of the human endothelial cell lines, HMEC-1 and EAhy-926, were examined in vitro.
RESULTS: Homogenous substrata of disc aggrecan inhibited endothelial cell adhesion and cell spreading in a concentration dependent manner. In substrata choice assays, endothelial cells seeded onto collagen type I migrated over the collagen until they encountered substrata of disc aggrecan, where they either stopped migrating, retreated onto the collagen, or, more commonly, changed direction to align along the collagen-aggrecan border. The inhibitory effect of aggrecan on endothelial cell migration was concentration dependent, and reduced by enzymatic treatment of the aggrecan monomers with a combination of chondroitinase ABC and keratinase/keratinase II. Anulus fibrosus aggrecan was more inhibitory to endothelial cell adhesion than nucleus pulposus aggrecan. However, this difference did not relate to the extent to which the different aggrecan isolates were charged, as determined by colorimetric assay with 1,9-dimethylmethylene blue, or to marked differences in the distribution of chondroitin sulfated and keratan sulfated side chains.
CONCLUSIONS: Human intervertebral disc aggrecan is inhibitory to endothelial cell migration, and this inhibitory effect appears to depend, in part, on the presence of glycosaminoglycan side chains on the aggrecan monomer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897827     DOI: 10.1097/01.brs.0000162624.95262.73

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  52 in total

1.  Intact glycosaminoglycans from intervertebral disc-derived notochordal cell-conditioned media inhibit neurite growth while maintaining neuronal cell viability.

Authors:  Devina Purmessur; Marisa C Cornejo; Samuel K Cho; Peter J Roughley; Robert J Linhardt; Andrew C Hecht; James C Iatridis
Journal:  Spine J       Date:  2015-02-07       Impact factor: 4.166

2.  Relationship between neovascularization and degenerative changes in herniated lumbar intervertebral discs.

Authors:  Tõnu Rätsep; Ave Minajeva; Toomas Asser
Journal:  Eur Spine J       Date:  2013-06-05       Impact factor: 3.134

3.  FasL on human nucleus pulposus cells prevents angiogenesis in the disc by inducing Fas-mediated apoptosis of vascular endothelial cells.

Authors:  Zhen Sun; Zhong-Yuan Wan; Yun-Shan Guo; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

4.  Catabolic effects of endothelial cell-derived microparticles on disc cells: Implications in intervertebral disc neovascularization and degeneration.

Authors:  Pedro H I Pohl; Thomas P Lozito; Thais Cuperman; Takashi Yurube; Hong J Moon; Kevin Ngo; Rocky S Tuan; Claudette St Croix; Gwendolyn A Sowa; Luciano M R Rodrigues; James D Kang; Nam V Vo
Journal:  J Orthop Res       Date:  2016-06-14       Impact factor: 3.494

Review 5.  Disc cell therapies: critical issues.

Authors:  Marta Tibiletti; Nevenka Kregar Velikonja; Jill P G Urban; Jeremy C T Fairbank
Journal:  Eur Spine J       Date:  2014-02-08       Impact factor: 3.134

Review 6.  Defects in intervertebral disc and spine during development, degeneration, and pain: New research directions for disc regeneration and therapy.

Authors:  Sarthak Mohanty; Chitra L Dahia
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-04-11       Impact factor: 5.814

Review 7.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 8.  Chronic low back pain: a mini-review on pharmacological management and pathophysiological insights from clinical and pre-clinical data.

Authors:  Thomas S W Park; Andy Kuo; Maree T Smith
Journal:  Inflammopharmacology       Date:  2018-05-12       Impact factor: 4.473

Review 9.  Mechanisms that drive bone pain across the lifespan.

Authors:  Patrick W Mantyh
Journal:  Br J Clin Pharmacol       Date:  2018-11-22       Impact factor: 4.335

10.  Expression of semaphorin 3A and its receptors in the human intervertebral disc: potential role in regulating neural ingrowth in the degenerate intervertebral disc.

Authors:  Sotonye K Tolofari; Stephen M Richardson; Anthony J Freemont; Judith A Hoyland
Journal:  Arthritis Res Ther       Date:  2010-01-05       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.